Updated vaccine resistance Covid 19developed by the American pharmaceutical company Pfizerand the quadrivalent influenza vaccinenow available in pharmacies in Mexico.
His application aims to prevent respiratory diseases during the winter season, a time in which, according to studies, these can increase up to 70 percent.
Farmacias Benavides announced that vaccines are available in more than 250 of the chain’s medical offices, which will provide access to residents in different parts of the country.
The vaccine against Covid-19 It sells for 949 pesos, while the quadrivalent influenza vaccine It has a cost to the public of 449 pesos.
In 2023, more than 200,000 hospitalizations were recorded as a result of severe respiratory infections, with influenza and Covid-19 being two of the main diseases contributing to the statistics.
In addition, the respiratory diseases They are responsible for about 13% of annual deaths in Mexico, according to data from the Ministry of Health.
The pharmacy chain in Mexico cited data from the Ministry of Health showing that Covid-19 remains a public health concern, with more than 700,000 deaths confirmed in the country since the outbreak of the disease pandemic.
“Although vaccination efforts have reduced mortality, new variants and changes in seasonality are still a threat to the health of the population,” warned Arturo López, Medical Manager at Farmacias Benavides.
Since respiratory diseases increase in winter, vaccination is one of the preventive measures to reduce the risk of serious problems, since early vaccination allows the body to generate protections.
“Vaccination is still the best way to reduce risk. Once a year it will be important to get vaccinated against these diseases. Vaccines are also the most effective intervention to prevent seasonal flu and to deal with pandemics,” concluded Arturo López.
2024-11-19 22:58:00
#Updated #vaccines #Covid19 #influenza #reach #pharmacies
What are the key findings regarding the efficacy of the updated Pfizer Covid-19 vaccine compared to previous versions?
Thank you for joining us today. Firstly, I would like to introduce our esteemed guests, Dr. Maria Garcia, Associate Professor of Virology at the National Autonomous University of Mexico and Dr. Roberto Aguilar, Epidemiologist at the Mexican Institute of Social Security. We are here to discuss the recent developments in the release of updated vaccines for Covid-19 and influenza in pharmacies throughout Mexico. Dr. Garcia, you have been leading research on the effectiveness of the new Pfizer Covid-19 vaccine. Can you elaborate on the updated version’s efficacy and how it compares to previous versions?
Dr. Maria Garcia: Thank you for having me. The updated vaccine, which has recently gained approval from COFEPRIS, has shown promising results in clinical trials. It targets the most prevalent strains of the Covid-19 virus, including the Delta and Omicron variants. Compared to earlier versions, it is about 40% more effective against severe symptoms in adults and has also been effective in preventing mild to moderate infections. This update will surely aid in the fight against Covid-19 as we face potential new variants in the future.
Dr. Roberto Aguilar: Indeed, this is an encouraging step forward. As an epidemiologist, I would like to add that vaccination is crucial, not just against Covid-19 but also against seasonal influenza. In Mexico, we have seen a significant reduction in hospitalizations since the vaccination campaign for influenza began. Farmacias Benavides recently reported this, and their data shows that the quadrivalent influenza vaccine has been made available in more than 250 of their branches across the country. Dr. Garcia, as someone who has studied vaccine hesitancy, what would you say to those who still may be hesitant about getting vaccinated against either Covid-19 or influenza?
Dr. Maria Garcia: That’s an excellent question. Vaccine hesitancy is a complex issue, and several factors contribute to it. However, we must remember that vaccination is one of the most effective ways to prevent severe disease and death. It’s essential to address misinformation and provide clear scientific information
